, /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held , in Cairns, Australia. Details of the presentation are as follows: Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.
Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for , , and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing. Armata Pharmaceuticals, Inc.
310-665-2928 LifeSci Advisors, LLC 212-915-2569 SOURCE Armata Pharmaceuticals, Inc..
